LifeMD (LFMD) director DiTrolio receives 35,000-share stock grant vesting 2027

Rhea-AI Filing Summary

LifeMD, Inc. director Joseph DiTrolio reported an acquisition of 35,000 shares of common stock as a grant/award, with no cash price per share. These are restricted shares that vest on June 1, 2027. Following this grant, DiTrolio directly holds 308,413 shares of LifeMD common stock.

Insider Trade Summary

Net Buyer: 35,000 shares

Net Buy 1 txn

Insider DiTrolio Joseph

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	35,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 308,413 shares (Direct)

Footnotes (1)

1. F1. The grant of restricted shares vests on June 1, 2027.

Key Figures

Shares granted: 35,000 shares Transaction price per share: $0.0000 per share Holdings after transaction: 308,413 shares +2 more

5 metrics

Shares granted 35,000 shares Restricted stock grant of common stock to director on August 11, 2026

Transaction price per share $0.0000 per share Reported price for the 35,000-share grant/award acquisition

Holdings after transaction 308,413 shares Total direct LifeMD common stock held by Joseph DiTrolio after the grant

Vesting date June 1, 2027 Vesting date of the 35,000 restricted shares granted to the director

Transaction date August 11, 2026 Date of the reported grant/award acquisition of common stock

Key Terms

restricted shares, grant/award acquisition, Rule 10b5-1

3 terms

restricted shares financial

"The grant of restricted shares vests on June 1, 2027."

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

grant/award acquisition financial

"The transaction is classified as a grant/award acquisition of common stock."

Rule 10b5-1 regulatory

"The Rule 10b5-1 checkbox is not marked as being pursuant to a trading plan."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What did LifeMD (LFMD) director Joseph DiTrolio report on this Form 4?

Director Joseph DiTrolio reported receiving a grant of 35,000 shares of LifeMD common stock. The shares were acquired as a grant/award with a reported price of $0.0000 per share, increasing his direct holdings to 308,413 shares.

How many LifeMD (LFMD) shares did Joseph DiTrolio acquire and at what price?

Joseph DiTrolio acquired 35,000 shares of LifeMD common stock in a grant transaction. The reported transaction price was $0.0000 per share, indicating this was a compensation-related award rather than an open-market purchase of stock.

When do Joseph DiTrolio’s new LifeMD (LFMD) restricted shares vest?

The 35,000 restricted shares granted to Joseph DiTrolio vest on June 1, 2027. Until vesting, these shares remain subject to restrictions as described, aligning the director’s compensation with a multi-year timeframe for LifeMD’s performance and service.

What is Joseph DiTrolio’s total LifeMD (LFMD) shareholding after this grant?

After the 35,000-share grant, Joseph DiTrolio directly holds 308,413 shares of LifeMD common stock. This figure represents his direct ownership position as reported following the transaction dated August 11, 2026, in the Form 4 filing.

Was the LifeMD (LFMD) Form 4 transaction under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as being pursuant to a trading plan. The transaction is reported as a grant/award acquisition of restricted shares, distinct from open-market trades executed under a preset 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 09:25 PM Accepted by SEC EDGAR 08/13/2026 - 09:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DiTrolio Joseph

(Last) (First) (Middle)

C/O LIFEMD, INC.

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2026		A		35,000(1)	A	$0	308,413	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant of restricted shares vests on June 1, 2027.

	/s/ Joseph DiTriolio	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)